While MEK-ERK activation is necessary and sufficient to mediate Raf-induced androgen receptor (AR) downregulation in prostate cancer cell lines irrespective of AR sensitivity [53], patients who have failed hormone ablation therapy display elevated ERK1/2 signal activation in recurrent tumors [54]. This evidence concerns the gene MAPK1 and prostate carcinoma.